文献速递瓣膜病与结构性心脏病冠心病

STS-ACC经导管瓣膜治疗注册研究:2011-2019年TAVR真实世界数据与低危患者首次报告

STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该注册研究汇总2011至2019年美国全部州276,316例经导管主动脉瓣置换(TAVR)患者数据,2019年TAVR量超过外科主动脉瓣置换(72,991 vs. 57,626)。2019年首次报告8,395例低危患者;全队列股动脉入路达95.3%,住院2天,90.3%出院回家。30天死亡率由7.2%降至2.5%,卒中由2.75%降至2.3%,起搏器需求无变化(10.9%至10.8%)。

要点

  • 2019年美国TAVR量已超过外科主动脉瓣置换(72,991 vs. 57,626)。
  • 30天死亡率由2011年7.2%降至2019年2.5%,卒中由2.75%降至2.3%。
  • 起搏器需求未见下降(10.9%至10.8%),为需关注并发症。

核心结论

  • TAVR在美国已扩展至极低危至低危患者,真实世界30天死亡率和卒中下降,但起搏器需求未改善。

研究设计与样本

  • STS-ACC TVT注册研究,2011至2019年纳入美国全部州276,316例TAVR患者。
  • 2019年首次报告8,395例低危TAVR患者。

主要发现

  • 2019年TAVR量达72,991例,超过外科主动脉瓣置换的57,626例。
  • 2019年全队列股动脉入路95.3%,住院2天,90.3%出院回家。
  • 30天死亡率由7.2%降至2.5%,卒中由2.75%降至2.3%,起搏器需求由10.9%至10.8%。
  • 1年时8/10患者存活且患者报告结局可接受。

临床怎么用

  • TAVR已覆盖外科低危患者,临床决策需结合真实世界结局与起搏器风险。
  • 股动脉入路为主流(95.3%),住院时间短(2天),多数患者可出院回家(90.3%)。

局限性

  • 本文为注册研究,未报告低危患者亚组的具体结局数值。
  • COVID-19影响及站点绩效将在后续研究中分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The STS-ACC TVT Registry (Society of Thoracic Surgeons-American College of Cardiology Transcatheter Valve Therapy Registry) from 2011 to 2019 has collected data on 276,316 patients undergoing transcatheter aortic valve replacement (TAVR) at sites in all U.S. states. Volumes have increased every year, exceeding surgical aortic valve replacement in 2019 (72,991 vs. 57,626), and it is now performed in all U.S. states. TAVR now extends from extreme- to low-risk patients. This is the first presentation on 8,395 low-risk patients treated in 2019. In 2019, for the entire cohort, femoral access increased to 95.3%, hospital stay was 2 days, and 90.3% were discharged home. Since 2011, the 30-day mortality rate has decreased (7.2% to 2.5%), stroke has started to decrease (2.75% to 2.3%), but pacemaker need is unchanged (10.9% to 10.8%). Alive with acceptable patient-reported outcomes is achieved in 8 of 10 patients at 1 year. The Registry is a national resource to improve care and analyze TAVR's evolution. Real-world outcomes, site performance, and the impact of coronavirus disease 2019 will be subsequently studied. (STS/ACC Transcatheter Valve Therapy Registry [TVT Registry]; NCT01737528).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020. PMID: 33213729. doi:10.1016/j.jacc.2020.09.595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。